Robert Richard Flavell MD, PhD, Presenter: Nothing to Disclose

David Michael Naeger MD, Abstract Co-Author: Nothing to Disclose

Carina Mari Aparici MD, Abstract Co-Author: Nothing to Disclose

Randall A. Hawkins MD, PhD, Abstract Co-Author: Nothing to Disclose

Spencer Caton Behr MD, Abstract Co-Author: Research Grant, General Electric Company

The purpose of this exhibit is: 1. To review malignancies that do not demonstrate FDG uptake at PET/CT, a potential source of scan misinterpretation. 2. To understand the association of FDG uptake with malignant transformation and aggressive phenotype in other cancers.

1. Common non-FDG avid malignancies - Mucinous malignancies - Renal cell carcinoma - Low grade adenocarcinoma spectrum lesions of the lungs - Lesions smaller than 0.5 – 1 cm 2. Prognostic significance of FDG uptake in cancers that are frequently non-FDG avid - Hepatocellular carcinoma (HCC) - Lymphoma - Neuroendocrine tumors - Prostate cancer 3. Lesions that exhibit the “flip-flop” phenomenon in which FDG uptake is inversely correlates with another radiotracer - Neuroendocrine tumors - Thyroid cancer

http://abstract.rsna.org/uploads/2014/14015768/14015768_gd26.pdf

Flavell, R, Naeger, D, Mari Aparici, C, Hawkins, R, Behr, S, Non-FDG Avid Malignancy on PET/CT: Pitfalls and Prognostic Significance.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14015768.html